View ValuationBrooks Laboratories 将来の成長Future 基準チェック /06現在、 Brooks Laboratoriesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長22.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • 7hFirst quarter 2027 earnings released: ₹0.61 loss per share (vs ₹3.25 profit in 1Q 2026)First quarter 2027 results: ₹0.61 loss per share (down from ₹3.25 profit in 1Q 2026). Revenue: ₹231.4m (down 9.3% from 1Q 2026). Net loss: ₹17.9m (down 119% from profit in 1Q 2026). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Aug 12+ 2 more updatesBrooks Laboratories Limited to Report Q4, 2027 Results on May 30, 2027Brooks Laboratories Limited announced that they will report Q4, 2027 results on May 30, 2027お知らせ • Aug 10Brooks Laboratories Limited, Annual General Meeting, Sep 03, 2026Brooks Laboratories Limited, Annual General Meeting, Sep 03, 2026, at 09:00 Indian Standard Time.お知らせ • Aug 06Brooks Laboratories Limited to Report Q1, 2027 Results on Aug 13, 2026Brooks Laboratories Limited announced that they will report Q1, 2027 results on Aug 13, 2026お知らせ • Jul 17Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026Brooks Laboratories Limited had appointed Mr. Rajesh Mahajan as President Trading and Senior Management Personnel of the Company with effect from July 17, 2026. Mr. Rajesh Mahajan holds a Bachelor's Degree in Biology and an MBA in Marketing. He has over 20+ years of experience in the pharmaceutical industry, with extensive expertise in pharmaceutical formulations and manufacturing operations. He has been instrumental in the growth of Brooks Laboratories Limited's formulation business and also played a key role in planning and executing new projects and business development initiatives.お知らせ • Jun 20Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited (NSEI:BROOKS) for INR 1.1 billion.Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited (NSEI:BROOKS) for INR 1.1 billion on June 19, 2026. A cash consideration of INR 1.06 billion will be paid by Steriscience Specialties Private Limited.Upon completion, Steriscience Specialties Private Limited will own 67.33% stake in Brooks Steriscience Limited. The transaction is subject to approval of merger agreement by target board and approval by regulatory board / committee.Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹8.35 (vs ₹3.72 loss in FY 2025)Full year 2026 results: EPS: ₹8.35 (up from ₹3.72 loss in FY 2025). Revenue: ₹869.1m (up 5.3% from FY 2025). Net income: ₹245.8m (up ₹345.5m from FY 2025). Profit margin: 28% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • May 22Brooks Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Brooks Laboratories Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 29, 2026Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹53.73, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 11% over the past three years.Valuation Update With 7 Day Price Move • May 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹55.98, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 12% over the past three years.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 34%After last week's 34% share price gain to ₹71.57, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 6.3% over the past three years.Buy Or Sell Opportunity • Mar 23Now 30% undervalued after recent price dropOver the last 90 days, the stock has fallen 50% to ₹46.03. The fair value is estimated to be ₹65.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Meanwhile, the company has become profitable.New Risk • Mar 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risk Market cap is less than US$100m (₹1.63b market cap, or US$17.7m).Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹75.81, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 30x in the Life Sciences industry in India. Total loss to shareholders of 22% over the past three years.Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹1.87 (vs ₹1.75 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹1.87 (up from ₹1.75 loss in 3Q 2025). Revenue: ₹166.9m (down 57% from 3Q 2025). Net income: ₹55.0m (up ₹100.7m from 3Q 2025). Profit margin: 33% (up from net loss in 3Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Jan 30Brooks Laboratories Limited to Report Q3, 2026 Results on Feb 06, 2026Brooks Laboratories Limited announced that they will report Q3, 2026 results on Feb 06, 2026分析記事 • Dec 31Brooks Laboratories Limited (NSE:BROOKS) Not Doing Enough For Some Investors As Its Shares Slump 31%To the annoyance of some shareholders, Brooks Laboratories Limited ( NSE:BROOKS ) shares are down a considerable 31% in...New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹2.08b market cap, or US$23.1m).Valuation Update With 7 Day Price Move • Dec 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹77.77, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 28% over the past three years.分析記事 • Nov 22Impressive Earnings May Not Tell The Whole Story For Brooks Laboratories (NSE:BROOKS)Despite announcing strong earnings, Brooks Laboratories Limited's ( NSE:BROOKS ) stock was sluggish. We did some...Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹2.71 (vs ₹1.51 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.71 (up from ₹1.51 loss in 2Q 2025). Revenue: ₹238.4m (up 15% from 2Q 2025). Net income: ₹79.8m (up ₹119.4m from 2Q 2025). Profit margin: 34% (up from net loss in 2Q 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Nov 08Brooks Laboratories Limited to Report Q2, 2026 Results on Nov 14, 2025Brooks Laboratories Limited announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Sep 03Brooks Laboratories Limited, Annual General Meeting, Sep 26, 2025Brooks Laboratories Limited, Annual General Meeting, Sep 26, 2025, at 09:00 Indian Standard Time.Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹3.25 (vs ₹0.94 loss in 1Q 2025)First quarter 2026 results: EPS: ₹3.25 (up from ₹0.94 loss in 1Q 2025). Revenue: ₹257.3m (up 44% from 1Q 2025). Net income: ₹95.8m (up ₹120.0m from 1Q 2025). Profit margin: 37% (up from net loss in 1Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 09Brooks Laboratories Limited to Report Q1, 2026 Results on Aug 13, 2025Brooks Laboratories Limited announced that they will report Q1, 2026 results on Aug 13, 2025Reported Earnings • May 29Full year 2025 earnings released: ₹3.72 loss per share (vs ₹7.65 loss in FY 2024)Full year 2025 results: ₹3.72 loss per share (improved from ₹7.65 loss in FY 2024). Revenue: ₹834.4m (up 5.0% from FY 2024). Net loss: ₹99.7m (loss narrowed 49% from FY 2024). Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 18% per year.お知らせ • May 23Brooks Laboratories Limited to Report Q4, 2025 Results on May 28, 2025Brooks Laboratories Limited announced that they will report Q4, 2025 results on May 28, 2025New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹3.13b market cap, or US$35.8m).Reported Earnings • Feb 15Third quarter 2025 earnings released: ₹1.75 loss per share (vs ₹1.51 loss in 3Q 2024)Third quarter 2025 results: ₹1.75 loss per share (further deteriorated from ₹1.51 loss in 3Q 2024). Revenue: ₹384.5m (up 77% from 3Q 2024). Net loss: ₹45.7m (loss widened 18% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 15% per year.お知らせ • Feb 10Brooks Laboratories Limited to Report Q3, 2025 Results on Feb 13, 2025Brooks Laboratories Limited announced that they will report Q3, 2025 results on Feb 13, 2025お知らせ • Dec 26Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024Brooks Laboratories Limited approved the appointment of Ms. Krutika Mohan Rane, Associate Member of the Institute of Company Secretaries of India, having membership no. ACS-66310, as Company Secretary & Compliance Officer of the company in terms of provisions of Section 203 of the Companies Act, 2013 and Rule made thereunder and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 effective from 26 December 2024. Ms. Krutika Mohan Rane Is an Associate Member of the Institute of Company Secretaries of India (Icsi), with Membership Number Acs-66310. She Holds the Necessary Qualifications and Skills in Secretarial Compliance. Ms. Rane Is Also A Law Graduate and Has Gained Practical Experience in Corporate Law and Listing Regulations through Various Assignments.お知らせ • Dec 13Brooks Laboratories Limited announced that it expects to receive INR 750 million in fundingBROOKS LABORATORIES LIMITED announced a private placement to issue common shares for the gross proceeds of INR 750,000,000 on December 11, 2024. The transaction has been approved by shareholders of company.Recent Insider Transactions • Nov 19Insider recently sold ₹66m worth of stockOn the 14th of November, Aryan Mahajan sold around 480k shares on-market at roughly ₹137 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹90m more than they bought in the last 12 months.Reported Earnings • Nov 10Second quarter 2025 earnings released: ₹1.51 loss per share (vs ₹0.64 loss in 2Q 2024)Second quarter 2025 results: ₹1.51 loss per share (further deteriorated from ₹0.64 loss in 2Q 2024). Revenue: ₹209.9m (down 14% from 2Q 2024). Net loss: ₹39.6m (loss widened 142% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 07Brooks Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024Brooks Laboratories Limited announced that they will report Q2, 2025 results on Nov 09, 2024お知らせ • Oct 21Brooks Laboratories Limited Announces Cessation of Sonia Gupta as Independent DirectorBrooks Laboratories Limited announced that Sonia Gupta has completed her second and final term of five consecutive years as an Independent Director of the Company on 28th September, 2024 and consequently ceased to be an Independent Director of the Company effective from 29th September, 2024.お知らせ • Sep 20Brooks Laboratories Limited Announces Board AppointmentsBrooks Laboratories Limited at its AGM held on September 19, 2024 approved appointment of Mr. Lalit Mahajan, Dr. Usha Singh and Mr. Manav Mahajan as Independent Directors. Mr. Lalit Mahajan has been appointed as an Independent Director on the Board of the Company for a term of 5 consecutive years with effect from August 7, 2024, with approval of shareholders at the Annual general meeting of the Company. Mr. Lalit Mahajan, aged 59, has a master's Degree in Arts. He has vast experience of 20 years in marketing. His association brings years of professional experience to facilitate developing and implementing marketing strategy and analyze the market and competitors of the Organization. Dr. Usha Singh has been appointed as an Additional Independent Director on the Board of the Company for a term of 5 consecutive years with effect from August 7, 2024, with approval of shareholders at the Annual general meeting of the Company. Dr. Usha Singh, aged 56, has a M.Sc. (Physics), Ph.D. (Renewable Energy). She has vast experience in experimental Science. She has more than ten research papers of internationally published. Mr. Manav Mahajan has been appointed as an Additional Independent Director on the Board of the Company for a term of 5 consecutive years with effect from September 29, 2024, with approval of shareholders at the Annual general meeting of the Company. Mr. Manav Mahajan aged 48, has a degree in Bachelor's of Technology (Production Engineering) from Punjab Engineering College and has a vast experience in manufacturing and export of various commodities all over the world.New Risk • Sep 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₹101m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹3.75b market cap, or US$44.7m).Board Change • Sep 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Independent Director Sonia Gupta is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Aug 28Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024, at 09:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2025 earnings released: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024)First quarter 2025 results: ₹0.94 loss per share (improved from ₹1.81 loss in 1Q 2024). Revenue: ₹180.0m (up 15% from 1Q 2024). Net loss: ₹24.1m (loss narrowed 46% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Aug 06Brooks Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024Brooks Laboratories Limited announced that they will report Q1, 2025 results on Aug 14, 2024New Risk • Jun 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹101m free cash flow). Earnings have declined by 1.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Market cap is less than US$100m (₹2.11b market cap, or US$25.3m).Reported Earnings • May 21Full year 2024 earnings released: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023)Full year 2024 results: ₹7.67 loss per share (improved from ₹8.46 loss in FY 2023). Revenue: ₹804.4m (up 27% from FY 2023). Net loss: ₹195.9m (loss narrowed 6.3% from FY 2023). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 01Third quarter 2024 earnings released: ₹1.51 loss per share (vs ₹2.03 loss in 3Q 2023)Third quarter 2024 results: ₹1.51 loss per share (improved from ₹2.03 loss in 3Q 2023). Revenue: ₹219.0m (up 43% from 3Q 2023). Net loss: ₹38.8m (loss narrowed 23% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 24Brooks Laboratories Limited to Report Q3, 2024 Results on Jan 31, 2024Brooks Laboratories Limited announced that they will report Q3, 2024 results on Jan 31, 2024Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹0.64 loss per share (vs ₹3.19 loss in 2Q 2023)Second quarter 2024 results: ₹0.64 loss per share (improved from ₹3.19 loss in 2Q 2023). Revenue: ₹244.1m (up 35% from 2Q 2023). Net loss: ₹16.4m (loss narrowed 65% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 22Brooks Laboratories Limited Announces Director AppointmentsBrooks Laboratories Limited announced that at its AGM held on September 21, 2023, Dr. Durga Shankar Maity has been appointed as Whole Time Director of the company for a term of 5 years effective from July 7, 2023; Mr. Bhushan Singh Rana has been appointed as a Whole-time Director of the Company for a term of 5 years effective from August 23, 2023.お知らせ • Sep 01Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023, at 09:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31 March 2023 and the Report of directors and Auditors thereon; to reappoint Mr. Jitendra Pratap Singh, who retires by rotation, and being eligible, offers himself for reappointment; to ratify the remuneration of the Cost Auditors; to Approval for Related Party Transactions; to consider the appointment of Dr. Durga Shankar Maity as Whole Time Director of the Company; to consider the appointment of Mr. Bhushan Singh Rana as Whole Time Director of the Company; and to discuss other matters.New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹150m free cash flow). Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Market cap is less than US$100m (₹2.47b market cap, or US$29.9m).お知らせ • Aug 24+ 1 more updateBrooks Laboratories Limited Approves the Appointment of Bhushan Singh Rana as an Additional Director (Executive)Brooks Laboratories Limited at its meeting held on August 23, 2023 has approved appointment of Mr. Bhushan Singh Rana as an Additional Director (Executive) of the Company w.e.f. closing of business hours of August 23, 2023 as recommended by Nomination & Remuneration Committee of the Company. Mr. Bhushan Singh Rana as an Additional Director (Executive) till the conclusion of upcoming Annual General Meeting. Mr. Bhushan Singh Rana aged 68 years, has completed his Double M. A from Meerut University. He has vast experience of 36 years in Administrative Services.Reported Earnings • Aug 11First quarter 2024 earnings released: ₹1.81 loss per share (vs ₹3.80 loss in 1Q 2023)First quarter 2024 results: ₹1.81 loss per share (improved from ₹3.80 loss in 1Q 2023). Revenue: ₹157.6m (down 8.0% from 1Q 2023). Net loss: ₹44.7m (loss narrowed 35% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.お知らせ • Aug 03Brooks Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023Brooks Laboratories Limited announced that they will report Q1, 2024 results on Aug 10, 2023お知らせ • Jul 08+ 1 more updateBrooks Laboratories Limited Appoints Durga Shankar Maity as Additional DirectorBrooks Laboratories Limited at its board meeting held on July 7, 2023, approved appointment of Mr. Durga Shankar Maity as an Additional Director of the Company till the conclusion of upcoming Annual General Meeting with effect from July 7, 2023 as recommended by Nomination & Remuneration Committee of the Company. Mr. Durga Shankar Maity aged 59 years, has a PHD Degree in Chemistry. He has vast experience of 34 years in the Pharmaceutical Industry.Reported Earnings • Feb 15Third quarter 2023 earnings released: ₹2.03 loss per share (vs ₹3.14 loss in 3Q 2022)Third quarter 2023 results: ₹2.03 loss per share (improved from ₹3.14 loss in 3Q 2022). Revenue: ₹154.0m (down 21% from 3Q 2022). Net loss: ₹50.2m (loss narrowed 35% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 28Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Sep 07+ 1 more updateBrooks Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023Brooks Laboratories Limited announced that they will report Q3, 2023 results on Feb 14, 2023Reported Earnings • Aug 11First quarter 2023 earnings released: ₹3.80 loss per share (vs ₹0.47 loss in 1Q 2022)First quarter 2023 results: ₹3.80 loss per share (down from ₹0.47 loss in 1Q 2022). Revenue: ₹171.6m (down 23% from 1Q 2022). Net loss: ₹69.0m (loss widened ₹57.6m from 1Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.分析記事 • Jun 10Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Jun 04Full year 2022 earnings released: ₹7.82 loss per share (vs ₹7.84 loss in FY 2021)Full year 2022 results: ₹7.82 loss per share (up from ₹7.84 loss in FY 2021). Revenue: ₹919.9m (up 18% from FY 2021). Net loss: ₹161.9m (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Feb 22Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)How far off is Brooks Laboratories Limited ( NSE:BROOKS ) from its intrinsic value? Using the most recent financial...Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹3.14 loss per share (down from ₹1.03 loss in 3Q 2021). Revenue: ₹193.8m (down 7.4% from 3Q 2021). Net loss: ₹77.5m (loss widened 204% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings.分析記事 • Dec 08Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Nov 13Second quarter 2022 earnings released: ₹1.97 loss per share (vs ₹1.35 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹215.7m (down 26% from 2Q 2021). Net loss: ₹48.3m (down 244% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.Board Change • Sep 15Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Sonia Gupta was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Executive Departure • Sep 13Technical Director & Whole Time Director Suresh Garg has left the companyOn the 3rd of September, Suresh Garg's tenure as Technical Director & Whole Time Director ended after 2.0 years in the role. As of June 2021, Suresh still personally held only 410.00 shares (₹40k worth at the time). Suresh is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.08 years.Board Change • Sep 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Sonia Gupta was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Jul 07Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Jul 06Full year 2021 earnings released: ₹7.76 loss per share (vs ₹13.84 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹772.5m (up 11% from FY 2020). Net loss: ₹193.8m (loss narrowed 21% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Feb 12Third quarter 2021 earnings released: ₹1.03 loss per share (vs ₹1.67 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: ₹209.6m (up 5.4% from 3Q 2020). Net loss: ₹25.6m (loss narrowed 9.0% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year.Is New 90 Day High Low • Feb 12New 90-day low: ₹58.60The company is down 6.0% from its price of ₹62.25 on 14 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 9.0% over the same period.分析記事 • Jan 05Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Jan 04New 90-day high: ₹73.20The company is up 7.0% from its price of ₹68.25 on 06 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 20% over the same period.Is New 90 Day High Low • Dec 02New 90-day high: ₹71.75The company is up 79% from its price of ₹40.10 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day high: ₹68.75The company is up 134% from its price of ₹29.35 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 42% over the same period.分析記事 • Sep 22Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Sep 18First quarter earnings releasedOver the last 12 months the company has reported total losses of ₹235.3m, with losses widening by 59% from the prior year. Total revenue was ₹653.3m over the last 12 months, up 6.8% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Brooks Laboratories は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:BROOKS - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2026831132N/AN/AN/A3/31/20268572465893N/A12/31/2025888216N/AN/AN/A9/30/20259281402639N/A6/30/202590120N/AN/AN/A3/31/2025826-1001726N/A12/31/2024770-181N/AN/AN/A9/30/2024782-199-21-15N/A6/30/2024817-175N/AN/AN/A3/31/2024795-196-102-98N/A12/31/2023745-143N/AN/AN/A9/30/2023680-154-35-221N/A6/30/2023618-185N/AN/AN/A3/31/2023632-209-150-145N/A12/31/2022790-202N/AN/AN/A9/30/2022827-218-837-528N/A6/30/2022865-219N/AN/AN/A3/31/2022912-113-651-374N/A12/31/2021778-299N/AN/AN/A9/30/2021788-258-32177N/A6/30/2021872-176N/AN/AN/A3/31/2021772-194-1245N/A12/31/2020815-180N/AN/AN/A9/30/2020808-183-103-94N/A6/30/2020653-235N/AN/AN/A3/31/2020697-244N/A-94N/A12/31/2019660-154N/AN/AN/A9/30/2019612-149N/AN/AN/A6/30/2019612-148N/AN/AN/A3/31/2019550-148N/A-50N/A12/31/2018544-101N/AN/AN/A9/30/2018602-106N/AN/AN/A6/30/2018592-116N/AN/AN/A3/31/2018557-138N/A-62N/A12/31/2017555-124N/AN/AN/A9/30/2017487-93N/AN/AN/A6/30/2017493-56N/AN/AN/A3/31/201757517N/A96N/A12/31/201663975N/AN/AN/A9/30/201670798N/AN/AN/A6/30/2016774108N/AN/AN/A3/31/2016800106N/A81N/A12/31/201582884N/AN/AN/A9/30/201585673N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BROOKSの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BROOKSの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BROOKSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BROOKSの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BROOKSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BROOKSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/15 04:04終値2026/08/14 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Brooks Laboratories Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Anil BurraFirstCall Research
Reported Earnings • 7hFirst quarter 2027 earnings released: ₹0.61 loss per share (vs ₹3.25 profit in 1Q 2026)First quarter 2027 results: ₹0.61 loss per share (down from ₹3.25 profit in 1Q 2026). Revenue: ₹231.4m (down 9.3% from 1Q 2026). Net loss: ₹17.9m (down 119% from profit in 1Q 2026). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Aug 12+ 2 more updatesBrooks Laboratories Limited to Report Q4, 2027 Results on May 30, 2027Brooks Laboratories Limited announced that they will report Q4, 2027 results on May 30, 2027
お知らせ • Aug 10Brooks Laboratories Limited, Annual General Meeting, Sep 03, 2026Brooks Laboratories Limited, Annual General Meeting, Sep 03, 2026, at 09:00 Indian Standard Time.
お知らせ • Aug 06Brooks Laboratories Limited to Report Q1, 2027 Results on Aug 13, 2026Brooks Laboratories Limited announced that they will report Q1, 2027 results on Aug 13, 2026
お知らせ • Jul 17Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026Brooks Laboratories Limited had appointed Mr. Rajesh Mahajan as President Trading and Senior Management Personnel of the Company with effect from July 17, 2026. Mr. Rajesh Mahajan holds a Bachelor's Degree in Biology and an MBA in Marketing. He has over 20+ years of experience in the pharmaceutical industry, with extensive expertise in pharmaceutical formulations and manufacturing operations. He has been instrumental in the growth of Brooks Laboratories Limited's formulation business and also played a key role in planning and executing new projects and business development initiatives.
お知らせ • Jun 20Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited (NSEI:BROOKS) for INR 1.1 billion.Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited (NSEI:BROOKS) for INR 1.1 billion on June 19, 2026. A cash consideration of INR 1.06 billion will be paid by Steriscience Specialties Private Limited.Upon completion, Steriscience Specialties Private Limited will own 67.33% stake in Brooks Steriscience Limited. The transaction is subject to approval of merger agreement by target board and approval by regulatory board / committee.
Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹8.35 (vs ₹3.72 loss in FY 2025)Full year 2026 results: EPS: ₹8.35 (up from ₹3.72 loss in FY 2025). Revenue: ₹869.1m (up 5.3% from FY 2025). Net income: ₹245.8m (up ₹345.5m from FY 2025). Profit margin: 28% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • May 22Brooks Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Brooks Laboratories Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 29, 2026
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹53.73, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 11% over the past three years.
Valuation Update With 7 Day Price Move • May 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹55.98, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 12% over the past three years.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 34%After last week's 34% share price gain to ₹71.57, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 6.3% over the past three years.
Buy Or Sell Opportunity • Mar 23Now 30% undervalued after recent price dropOver the last 90 days, the stock has fallen 50% to ₹46.03. The fair value is estimated to be ₹65.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Meanwhile, the company has become profitable.
New Risk • Mar 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risk Market cap is less than US$100m (₹1.63b market cap, or US$17.7m).
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹75.81, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 30x in the Life Sciences industry in India. Total loss to shareholders of 22% over the past three years.
Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹1.87 (vs ₹1.75 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹1.87 (up from ₹1.75 loss in 3Q 2025). Revenue: ₹166.9m (down 57% from 3Q 2025). Net income: ₹55.0m (up ₹100.7m from 3Q 2025). Profit margin: 33% (up from net loss in 3Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Jan 30Brooks Laboratories Limited to Report Q3, 2026 Results on Feb 06, 2026Brooks Laboratories Limited announced that they will report Q3, 2026 results on Feb 06, 2026
分析記事 • Dec 31Brooks Laboratories Limited (NSE:BROOKS) Not Doing Enough For Some Investors As Its Shares Slump 31%To the annoyance of some shareholders, Brooks Laboratories Limited ( NSE:BROOKS ) shares are down a considerable 31% in...
New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹2.08b market cap, or US$23.1m).
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹77.77, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 28% over the past three years.
分析記事 • Nov 22Impressive Earnings May Not Tell The Whole Story For Brooks Laboratories (NSE:BROOKS)Despite announcing strong earnings, Brooks Laboratories Limited's ( NSE:BROOKS ) stock was sluggish. We did some...
Reported Earnings • Nov 16Second quarter 2026 earnings released: EPS: ₹2.71 (vs ₹1.51 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹2.71 (up from ₹1.51 loss in 2Q 2025). Revenue: ₹238.4m (up 15% from 2Q 2025). Net income: ₹79.8m (up ₹119.4m from 2Q 2025). Profit margin: 34% (up from net loss in 2Q 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Nov 08Brooks Laboratories Limited to Report Q2, 2026 Results on Nov 14, 2025Brooks Laboratories Limited announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Sep 03Brooks Laboratories Limited, Annual General Meeting, Sep 26, 2025Brooks Laboratories Limited, Annual General Meeting, Sep 26, 2025, at 09:00 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹3.25 (vs ₹0.94 loss in 1Q 2025)First quarter 2026 results: EPS: ₹3.25 (up from ₹0.94 loss in 1Q 2025). Revenue: ₹257.3m (up 44% from 1Q 2025). Net income: ₹95.8m (up ₹120.0m from 1Q 2025). Profit margin: 37% (up from net loss in 1Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 09Brooks Laboratories Limited to Report Q1, 2026 Results on Aug 13, 2025Brooks Laboratories Limited announced that they will report Q1, 2026 results on Aug 13, 2025
Reported Earnings • May 29Full year 2025 earnings released: ₹3.72 loss per share (vs ₹7.65 loss in FY 2024)Full year 2025 results: ₹3.72 loss per share (improved from ₹7.65 loss in FY 2024). Revenue: ₹834.4m (up 5.0% from FY 2024). Net loss: ₹99.7m (loss narrowed 49% from FY 2024). Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 18% per year.
お知らせ • May 23Brooks Laboratories Limited to Report Q4, 2025 Results on May 28, 2025Brooks Laboratories Limited announced that they will report Q4, 2025 results on May 28, 2025
New Risk • Mar 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹3.13b market cap, or US$35.8m).
Reported Earnings • Feb 15Third quarter 2025 earnings released: ₹1.75 loss per share (vs ₹1.51 loss in 3Q 2024)Third quarter 2025 results: ₹1.75 loss per share (further deteriorated from ₹1.51 loss in 3Q 2024). Revenue: ₹384.5m (up 77% from 3Q 2024). Net loss: ₹45.7m (loss widened 18% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 15% per year.
お知らせ • Feb 10Brooks Laboratories Limited to Report Q3, 2025 Results on Feb 13, 2025Brooks Laboratories Limited announced that they will report Q3, 2025 results on Feb 13, 2025
お知らせ • Dec 26Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024Brooks Laboratories Limited approved the appointment of Ms. Krutika Mohan Rane, Associate Member of the Institute of Company Secretaries of India, having membership no. ACS-66310, as Company Secretary & Compliance Officer of the company in terms of provisions of Section 203 of the Companies Act, 2013 and Rule made thereunder and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 effective from 26 December 2024. Ms. Krutika Mohan Rane Is an Associate Member of the Institute of Company Secretaries of India (Icsi), with Membership Number Acs-66310. She Holds the Necessary Qualifications and Skills in Secretarial Compliance. Ms. Rane Is Also A Law Graduate and Has Gained Practical Experience in Corporate Law and Listing Regulations through Various Assignments.
お知らせ • Dec 13Brooks Laboratories Limited announced that it expects to receive INR 750 million in fundingBROOKS LABORATORIES LIMITED announced a private placement to issue common shares for the gross proceeds of INR 750,000,000 on December 11, 2024. The transaction has been approved by shareholders of company.
Recent Insider Transactions • Nov 19Insider recently sold ₹66m worth of stockOn the 14th of November, Aryan Mahajan sold around 480k shares on-market at roughly ₹137 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹90m more than they bought in the last 12 months.
Reported Earnings • Nov 10Second quarter 2025 earnings released: ₹1.51 loss per share (vs ₹0.64 loss in 2Q 2024)Second quarter 2025 results: ₹1.51 loss per share (further deteriorated from ₹0.64 loss in 2Q 2024). Revenue: ₹209.9m (down 14% from 2Q 2024). Net loss: ₹39.6m (loss widened 142% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 07Brooks Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024Brooks Laboratories Limited announced that they will report Q2, 2025 results on Nov 09, 2024
お知らせ • Oct 21Brooks Laboratories Limited Announces Cessation of Sonia Gupta as Independent DirectorBrooks Laboratories Limited announced that Sonia Gupta has completed her second and final term of five consecutive years as an Independent Director of the Company on 28th September, 2024 and consequently ceased to be an Independent Director of the Company effective from 29th September, 2024.
お知らせ • Sep 20Brooks Laboratories Limited Announces Board AppointmentsBrooks Laboratories Limited at its AGM held on September 19, 2024 approved appointment of Mr. Lalit Mahajan, Dr. Usha Singh and Mr. Manav Mahajan as Independent Directors. Mr. Lalit Mahajan has been appointed as an Independent Director on the Board of the Company for a term of 5 consecutive years with effect from August 7, 2024, with approval of shareholders at the Annual general meeting of the Company. Mr. Lalit Mahajan, aged 59, has a master's Degree in Arts. He has vast experience of 20 years in marketing. His association brings years of professional experience to facilitate developing and implementing marketing strategy and analyze the market and competitors of the Organization. Dr. Usha Singh has been appointed as an Additional Independent Director on the Board of the Company for a term of 5 consecutive years with effect from August 7, 2024, with approval of shareholders at the Annual general meeting of the Company. Dr. Usha Singh, aged 56, has a M.Sc. (Physics), Ph.D. (Renewable Energy). She has vast experience in experimental Science. She has more than ten research papers of internationally published. Mr. Manav Mahajan has been appointed as an Additional Independent Director on the Board of the Company for a term of 5 consecutive years with effect from September 29, 2024, with approval of shareholders at the Annual general meeting of the Company. Mr. Manav Mahajan aged 48, has a degree in Bachelor's of Technology (Production Engineering) from Punjab Engineering College and has a vast experience in manufacturing and export of various commodities all over the world.
New Risk • Sep 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₹101m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹3.75b market cap, or US$44.7m).
Board Change • Sep 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Independent Director Sonia Gupta is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Aug 28Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024, at 09:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2025 earnings released: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024)First quarter 2025 results: ₹0.94 loss per share (improved from ₹1.81 loss in 1Q 2024). Revenue: ₹180.0m (up 15% from 1Q 2024). Net loss: ₹24.1m (loss narrowed 46% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06Brooks Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024Brooks Laboratories Limited announced that they will report Q1, 2025 results on Aug 14, 2024
New Risk • Jun 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹101m free cash flow). Earnings have declined by 1.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Market cap is less than US$100m (₹2.11b market cap, or US$25.3m).
Reported Earnings • May 21Full year 2024 earnings released: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023)Full year 2024 results: ₹7.67 loss per share (improved from ₹8.46 loss in FY 2023). Revenue: ₹804.4m (up 27% from FY 2023). Net loss: ₹195.9m (loss narrowed 6.3% from FY 2023). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 01Third quarter 2024 earnings released: ₹1.51 loss per share (vs ₹2.03 loss in 3Q 2023)Third quarter 2024 results: ₹1.51 loss per share (improved from ₹2.03 loss in 3Q 2023). Revenue: ₹219.0m (up 43% from 3Q 2023). Net loss: ₹38.8m (loss narrowed 23% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 24Brooks Laboratories Limited to Report Q3, 2024 Results on Jan 31, 2024Brooks Laboratories Limited announced that they will report Q3, 2024 results on Jan 31, 2024
Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹0.64 loss per share (vs ₹3.19 loss in 2Q 2023)Second quarter 2024 results: ₹0.64 loss per share (improved from ₹3.19 loss in 2Q 2023). Revenue: ₹244.1m (up 35% from 2Q 2023). Net loss: ₹16.4m (loss narrowed 65% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 22Brooks Laboratories Limited Announces Director AppointmentsBrooks Laboratories Limited announced that at its AGM held on September 21, 2023, Dr. Durga Shankar Maity has been appointed as Whole Time Director of the company for a term of 5 years effective from July 7, 2023; Mr. Bhushan Singh Rana has been appointed as a Whole-time Director of the Company for a term of 5 years effective from August 23, 2023.
お知らせ • Sep 01Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023, at 09:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31 March 2023 and the Report of directors and Auditors thereon; to reappoint Mr. Jitendra Pratap Singh, who retires by rotation, and being eligible, offers himself for reappointment; to ratify the remuneration of the Cost Auditors; to Approval for Related Party Transactions; to consider the appointment of Dr. Durga Shankar Maity as Whole Time Director of the Company; to consider the appointment of Mr. Bhushan Singh Rana as Whole Time Director of the Company; and to discuss other matters.
New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹150m free cash flow). Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Market cap is less than US$100m (₹2.47b market cap, or US$29.9m).
お知らせ • Aug 24+ 1 more updateBrooks Laboratories Limited Approves the Appointment of Bhushan Singh Rana as an Additional Director (Executive)Brooks Laboratories Limited at its meeting held on August 23, 2023 has approved appointment of Mr. Bhushan Singh Rana as an Additional Director (Executive) of the Company w.e.f. closing of business hours of August 23, 2023 as recommended by Nomination & Remuneration Committee of the Company. Mr. Bhushan Singh Rana as an Additional Director (Executive) till the conclusion of upcoming Annual General Meeting. Mr. Bhushan Singh Rana aged 68 years, has completed his Double M. A from Meerut University. He has vast experience of 36 years in Administrative Services.
Reported Earnings • Aug 11First quarter 2024 earnings released: ₹1.81 loss per share (vs ₹3.80 loss in 1Q 2023)First quarter 2024 results: ₹1.81 loss per share (improved from ₹3.80 loss in 1Q 2023). Revenue: ₹157.6m (down 8.0% from 1Q 2023). Net loss: ₹44.7m (loss narrowed 35% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.
お知らせ • Aug 03Brooks Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023Brooks Laboratories Limited announced that they will report Q1, 2024 results on Aug 10, 2023
お知らせ • Jul 08+ 1 more updateBrooks Laboratories Limited Appoints Durga Shankar Maity as Additional DirectorBrooks Laboratories Limited at its board meeting held on July 7, 2023, approved appointment of Mr. Durga Shankar Maity as an Additional Director of the Company till the conclusion of upcoming Annual General Meeting with effect from July 7, 2023 as recommended by Nomination & Remuneration Committee of the Company. Mr. Durga Shankar Maity aged 59 years, has a PHD Degree in Chemistry. He has vast experience of 34 years in the Pharmaceutical Industry.
Reported Earnings • Feb 15Third quarter 2023 earnings released: ₹2.03 loss per share (vs ₹3.14 loss in 3Q 2022)Third quarter 2023 results: ₹2.03 loss per share (improved from ₹3.14 loss in 3Q 2022). Revenue: ₹154.0m (down 21% from 3Q 2022). Net loss: ₹50.2m (loss narrowed 35% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 28Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Sep 07+ 1 more updateBrooks Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023Brooks Laboratories Limited announced that they will report Q3, 2023 results on Feb 14, 2023
Reported Earnings • Aug 11First quarter 2023 earnings released: ₹3.80 loss per share (vs ₹0.47 loss in 1Q 2022)First quarter 2023 results: ₹3.80 loss per share (down from ₹0.47 loss in 1Q 2022). Revenue: ₹171.6m (down 23% from 1Q 2022). Net loss: ₹69.0m (loss widened ₹57.6m from 1Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
分析記事 • Jun 10Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Jun 04Full year 2022 earnings released: ₹7.82 loss per share (vs ₹7.84 loss in FY 2021)Full year 2022 results: ₹7.82 loss per share (up from ₹7.84 loss in FY 2021). Revenue: ₹919.9m (up 18% from FY 2021). Net loss: ₹161.9m (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Feb 22Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)How far off is Brooks Laboratories Limited ( NSE:BROOKS ) from its intrinsic value? Using the most recent financial...
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹3.14 loss per share (down from ₹1.03 loss in 3Q 2021). Revenue: ₹193.8m (down 7.4% from 3Q 2021). Net loss: ₹77.5m (loss widened 204% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings.
分析記事 • Dec 08Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Nov 13Second quarter 2022 earnings released: ₹1.97 loss per share (vs ₹1.35 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹215.7m (down 26% from 2Q 2021). Net loss: ₹48.3m (down 244% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
Board Change • Sep 15Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Sonia Gupta was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Executive Departure • Sep 13Technical Director & Whole Time Director Suresh Garg has left the companyOn the 3rd of September, Suresh Garg's tenure as Technical Director & Whole Time Director ended after 2.0 years in the role. As of June 2021, Suresh still personally held only 410.00 shares (₹40k worth at the time). Suresh is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.08 years.
Board Change • Sep 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Sonia Gupta was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Jul 07Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Jul 06Full year 2021 earnings released: ₹7.76 loss per share (vs ₹13.84 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹772.5m (up 11% from FY 2020). Net loss: ₹193.8m (loss narrowed 21% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 12Third quarter 2021 earnings released: ₹1.03 loss per share (vs ₹1.67 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: ₹209.6m (up 5.4% from 3Q 2020). Net loss: ₹25.6m (loss narrowed 9.0% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year.
Is New 90 Day High Low • Feb 12New 90-day low: ₹58.60The company is down 6.0% from its price of ₹62.25 on 14 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 9.0% over the same period.
分析記事 • Jan 05Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Jan 04New 90-day high: ₹73.20The company is up 7.0% from its price of ₹68.25 on 06 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 20% over the same period.
Is New 90 Day High Low • Dec 02New 90-day high: ₹71.75The company is up 79% from its price of ₹40.10 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day high: ₹68.75The company is up 134% from its price of ₹29.35 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 42% over the same period.
分析記事 • Sep 22Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Sep 18First quarter earnings releasedOver the last 12 months the company has reported total losses of ₹235.3m, with losses widening by 59% from the prior year. Total revenue was ₹653.3m over the last 12 months, up 6.8% from the prior year.